BetterLife Pharma appointed Charles Duncan as a director and audit committee chair, granting 500,000 Options at $0.285 plus 125,000 more at the same price. Investors also have Warrant exercise terms and $127,500 in gross proceeds to assess alongside the new board appointment.

Key Highlights

  • A further 125,000 stock options were granted to Charles Duncan at an exercise price of $0.285.
  • BetterLife Pharma received $127,500 in gross proceeds from 850,000 exercised warrants.
  • Duncan is also a director of Vanda Pharmaceuticals and leads biotech strategy and development at Gilmartin Group.

BetterLife Pharma Inc. (OTC: BETRF) appointed Charles Duncan, PhD, as a director and chair of its audit committee in August 2026. The appointment came with 500,000 stock options exercisable at $0.285 per share, alongside a further option grant carrying the same exercise price.

$0.285 Option Grants Accompany Board Appointment

The initial options cover the purchase of 500,000 BetterLife common shares. A separate grant covers 125,000 additional stock options at $0.285. The grants were made in connection with Duncan’s appointment as director and audit committee chair. Duncan is described as a biotechnology strategist, board director and former Wall Street biotechnology analyst with experience advising biopharmaceutical investors, management teams and boards. He also sits on the board of Vanda Pharmaceuticals.

$127,500 Gross Proceeds From Warrant Exercise

The company issued 850,000 common shares in connection with those exercises at $0.1 per share. The warrant activity therefore resulted in both stated cash proceeds and the issuance of common stock. The material change date was September 10, 2026. BetterLife’s report was signed by Chief Financial Officer Moira Ong on September 11, 2026.